To further explore the therapeutic potential of activating GPR84 signaling in cancer, we first showed that activation of the GPR84-Gi signaling axis by the commonly used synthetic GPR84 agonist 6-OAU (6-n-octylaminouracil)7,11 could synergize with an anti-CD47 antibody24,25 that disrupts the binding of CD47 to its receptor, Sirpa23, on macrophages to induce phagocytosis of cancer cells by macrophages. This evidence concerns the gene CD47 and cancer.